Close

Anti-SPINT2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1618-FY)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-SPINT2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • SPINT2
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-1618-FY CBFYH-3308 Rat Mouse IgG2 Mouse recombinant protein of the common extracellular region of HAI-2 isoforms
DMAb-1619-FY CBFYH-2780 Mouse Human IgG1 Mouse myeloma cell line NS0-derived recombinant human HAI-2, aa 28-197
DMAb-1620-FY CBFYH-2781 Mouse Human IgG1 Human recombinant HAI-2 EC domain
DMAb-1621-FY CBFYH-2782 Rabbit Human IgG
DMAb-3241-FY CBFYC-0045 Mouse Human IgG1 Recombinant Human CD200 Protein
DMAb-3242-FY CBFYC-0098 Rabbit Mouse IgG Recombinant Mouse CD200 protein (50074-M08H)
DMAb-3243-FY CBFYC-3137 Rabbit Mouse IgG Recombinant Mouse CD200 protein
DMAb-2875-CQ CBXS-5889 Rat IgG2
DMAb-2876-CQ CBXS-3763 Mouse IgG1
DMAb-2877-CQ CBXS-1161 Rabbit IgG Recombinant Mouse SPINT2 protein
DMAb-2878-CQ CBXS-2593 Mouse IgG1 Recombinant protein corresponding to human SPINT2 extracellular domain
DMAb-2879-CQ CBXS-2867 Mouse IgG2a, κ Full length recombinant protein corresponding to aa1-253 from SPINT2 (AAH11951) with GST tag
DMAb-M331-YC RM0089-7F52 Rat Mouse IgG2 Recombinant fragment corresponding to the extracellular region of Mouse HGFA Inhibitor 2.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-SPINT2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1618-FY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.